Topotecan Injection

Pfizer Inc

Revision date : 2012-01-31

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS08
Health risk rating 5
Safety risk rating 1
Environmental risk rating 1

Note: Ingredients listed on restricted chemical lists

EC/CAS

231-595-7/7647-01-0

Name of the chemical

Hydrochloric acid

Concentration

**

EC/CAS

215-185-5/1310-73-2

Name of the chemical

sodium hydroxide

Concentration

**

EC/CAS

200-711-8/69-65-8

Name of the chemical

D-mannitol C6H14O6

Concentration

*

EC/CAS

201-766-0/87-69-4

Name of the chemical

L-(+)-tartaric acid

Concentration

*

EC/CAS

231-791-2/7732-18-5

Name of the chemical

Water, distilled, conductivity or of similar purity H2O

Concentration

*

General Information

Version

1.0

Revision date

2012-01-31

Product name

Topotecan Injection

Product name

Topotecan Injection

Identification on the label/Trade name

Not applicable

Chemical name

Not determined

1.2.1 Relevant identified uses

Pharmaceutical product used as Antineoplastic

Emergency telephone

1-800-424-9300, +1-703-527-3887

Icons in SDS

M004 M009 M010 M011 M017 GHS08

Company Information

company name

Pfizer Inc

e-mail address of the competent person responsible for the Safety Data Sheet

pfizer-MSDS@pfizer.com

GHS Information

Signal word

DANGER

Hazard Codes

Hazard statements (CLP)

H340, H360D

Hazard statements

Code

Statements

H340

May cause genetic defects

Section 2

SECTION 2: Hazards identification

Appearance Light yellow to Green Lyophilized powder

Signal word

DANGER

Hazard statements

May damage the unborn child. May cause genetic defects.

Additional information

Short Term Accidental ingestion may cause effects similar to those seen in clinical use. Known Clinical Effects Adverse effects associated with therapeutic use include decreased white blood cells (leukopenia), gastrointestinal disturbances, diarrhea, fever, vasodilation, liver enzyme changes, fatigue, weakness, loss of hair, hypersensitivity reactions. EU Classification EU Indication of danger Toxic to Reproduction: Category 2 Mutagenic: Category 2 EU Hazard Symbols EU Risk Phrases R61 - May cause harm to the unborn child. R46 - May cause heritable genetic damage. Australian Hazard Classification (NOHSC)

Hazardous Ingredients

Non-Dangerous Goods Note This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

2.1 Classification of the substance or mixture

EU Indication of danger: Toxic to Reproduction: Category 2 Mutagenic: Category 2 EU Hazard Symbols: EU Risk Phrases: R61 - May cause harm to the unborn child. R46 - May cause heritable genetic damage. Australian Hazard Classification Hazardous Substance. Non-Dangerous Goods. (NOHSC)

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.